Menu

Rare T Cells Fight Cancer

A new approach to immunotherapy finds that the immune-cell clonotypes that come to the rescue start out at very low frequencies.

May 1, 2017
Jef Akst

T-CELL TARGET: Metastatic melanoma, pictured here, has been in the sights of immunotherapy developers. © ISTOCK.COM/BEHOLDINGEYE

The paper
A.G. Chapuis et al., “Tracking the fate and origin of clinically relevant adoptively transferred CD8+ T cells in vivo,” Sci Immunol, 2:eaal2568, 2017.

T-cell therapy
One approach used in cancer immunotherapy is to extract T cells from a patient’s blood, select a single clonotype that binds to a tumor antigen, expand it in culture, and reintroduce the cells to the body. Reaching therapeutic levels, however, might take several months, sometimes too late to save the patient.

The solution
Rather than generating a therapeutic population of lymphocytes from a single T cell, Fred Hutchinson Cancer Research Center immuno-oncologist Aude Chapuis and her colleagues decided to infuse patients with a polyclonal group of cells stimulated by a particular tumor antigen. “Instead of picking one cell and growing it out, we’re taking a lot of cells and growing them a lot less,” on the order of just four to six weeks, Chapuis says.

The result
The researchers tested the approach in 10 metastatic melanoma patients, tracking T cells in the blood via high-throughput sequencing. They found that, not only did the cells persist, the immunodominant clones that emerged existed only in very low frequencies in the body prior to the therapy. “The results demonstrate that long-lasting T cells are derived from a very rare, extant pool of largely inexperienced and probably naive T cells,” says coauthor Cassian Yee of the MD Anderson Cancer Center.

The long view
In the two patients who had complete remissions, a single dominant clone took over. “Sometimes there’s just this perfect fit and [one T cell type] just goes to town,” says Nicholas Restifo, who studies T cell–based immunotherapies at the National Cancer Institute and was not involved the study.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!